Figure 7: Cd4-Cre⁺ Zfp36l1^fl/fl Zfp36l2^fl/fl mice are protected from EAE.

A, Clinical EAE scoring in the indicated strains of mice. B, CD44 and MOG_38-49-I-A^b Tetramer staining on CD4⁺ T cells from the CNS of naïve or MOG_35-55 peptide immunized (day 14) Cd4-Cre⁻ Zfp36l1^fl/fl Zfp36l2^fl/fl and Cd4-Cre⁺ Zfp36l1^fl/fl Zfp36l2^fl/fl mice. C, Quantitation of CD4⁺ cells, CD44⁺ MOG_38-49-I-A^b Tetramer⁺ CD4⁺ T cells, the frequency of CD44⁺ MOG_38-49-I-A^b Tetramer⁺ CD4⁺ T cells, and the frequency of CD44⁺ MOG_38-49-I-A^b Tetramer⁻ CD4⁺ T cells in the CNS of naïve (pooled from 2 experiments, n=4/group) or immunized (day 14) Cd4-Cre⁻ Zfp36l1^fl/fl Zfp36l2^fl/fl and Cd4-Cre⁺ Zfp36l1^fl/fl Zfp36l2^fl/fl mice (pooled from 2 experiments, n=6/group). Data in A,C are mean ± s.e.m. Mann-Whitney U test between area under the curve for individual mice (A); two-way ANOVA with Šídák’s multiple comparisons test (C). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001; ns, not significant.